Jaime Rosenberg

All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

The FDA has approved sumatriptan nasal spray (Tosymra) for the acute treatment of migraine with or without aura in adults.

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

The increased risk of cancer is due in part to people living with HIV living longer, thanks to advances like antiretroviral therapy.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases

The years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

Through their Medicaid and Ryan White HIV/AIDS Programs, states play an integral role in ensuring access to care for people living with HIV.

A new study has found that fibromyalgia exacerbates depressive symptoms, migraine intensity, and migraine-related disability.

The study's findings show that patients with HIV will forgo short travel distances and wait times in order to access a health care provider with a positive attitude.

While the prevalence of neurological disabilities among children with HIV has drastically decreased since the emergence of antiretroviral therapy, the prevalence remains higher in this patient population

As people living with HIV now have a normal life expectancy, the burden of comorbidities is on the rise, and more than half of deaths in the patient population are attributable to the these comorbidities.

The HIV pandemic will likely continue to be a global challenge for the foreseeable future.

SensorRx is utilizing patient-generated health data that links to the physician in order to improve outcomes for the patient population.

Mobile health interventions have the potential to help people living with HIV improve engagement in care, promote medication adherence, and in turn, improve patient outcomes.

New study results indicate that an experimental mosaic HIV vaccine may have the potential to protect against a wide-range of global HIV strains.

Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine.

A study of 39 men found that those affected by migraine had higher levels of estradiol, an estrogen, than those without migraine.

Many individuals at high risk of getting HIV—including those who inject drugs, gay and bisexual men, and partners of people with HIV—are not screened annually and experience delays in diagnosis.

Employers that offer healthcare benefits, paid sick days, and disability insurance benefits will spend about $84,000 in annual migraine-related costs for every 1000 employees.

Timolol eyedrops may have a potential role in managing acute migraine for some patients.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Following their approval, anti–PD-1 agents reach a significant proportion of patients within a few months, according to new study findings.

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation.